Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kimia Biosciences' Board approved unaudited standalone financial results for Q3 FY26 (ended Dec 31, 2025) and nine months FY26. Revenue from operations stood at Rs 3,010.06 lakh, broadly flat YoY but down QoQ from Rs 3,399.93 lakh. Net profit jumped sharply to Rs 544.15 lakh (EPS Rs 1.15), up about 19% YoY and over 5x QoQ from Rs 101.51 lakh. For the nine-month period, revenue rose 8.7% YoY to Rs 8,768.40 lakh, but net profit slipped 7.4% to Rs 706.06 lakh versus Rs 762.07 lakh a year ago. The Board also approved the re-appointment of Mr. Sameer Goel as Managing Director for a fresh 5-year term (effective March 29, 2026 to March 28, 2031), subject to shareholder approval via postal ballot. Board committees were reconstituted following the induction of Mr. Kaku Vijaya Shekhar Reddy as Whole-time Director.
Q3 shows a strong sequential profit rebound on better margins, though the 9-month profit dip and softer revenue QoQ may limit positive reaction. The MD re-appointment ensures leadership continuity for shareholders.